Cargando…

The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke

BACKGROUND: Intravenous recombinant tissue plasminogen activator (rt-PA) is approved for use in selected patients with ischaemic stroke within 3 hours of symptom onset. IST-3 seeks to determine whether a wider range of patients may benefit. DESIGN: International, multi-centre, prospective, randomize...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandercock, Peter, Lindley, Richard, Wardlaw, Joanna, Dennis, Martin, Lewis, Steff, Venables, Graham, Kobayashi, Adam, Czlonkowska, Anna, Berge, Eivind, Slot, Karsten Bruins, Murray, Veronica, Peeters, Andre, Hankey, Graeme, Matz, Karl, Brainin, Michael, Ricci, Stefano, Celani, Maria Grazia, Righetti, Enrico, Cantisani, Teresa, Gubitz, Gord, Phillips, Steve, Arauz, Antonio, Prasad, Kameshwar, Correia, Manuel, Lyrer, Phillippe
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442584/
https://www.ncbi.nlm.nih.gov/pubmed/18559104
http://dx.doi.org/10.1186/1745-6215-9-37
_version_ 1782156704634372096
author Sandercock, Peter
Lindley, Richard
Wardlaw, Joanna
Dennis, Martin
Lewis, Steff
Venables, Graham
Kobayashi, Adam
Czlonkowska, Anna
Berge, Eivind
Slot, Karsten Bruins
Murray, Veronica
Peeters, Andre
Hankey, Graeme
Matz, Karl
Brainin, Michael
Ricci, Stefano
Celani, Maria Grazia
Righetti, Enrico
Cantisani, Teresa
Gubitz, Gord
Phillips, Steve
Arauz, Antonio
Prasad, Kameshwar
Correia, Manuel
Lyrer, Phillippe
author_facet Sandercock, Peter
Lindley, Richard
Wardlaw, Joanna
Dennis, Martin
Lewis, Steff
Venables, Graham
Kobayashi, Adam
Czlonkowska, Anna
Berge, Eivind
Slot, Karsten Bruins
Murray, Veronica
Peeters, Andre
Hankey, Graeme
Matz, Karl
Brainin, Michael
Ricci, Stefano
Celani, Maria Grazia
Righetti, Enrico
Cantisani, Teresa
Gubitz, Gord
Phillips, Steve
Arauz, Antonio
Prasad, Kameshwar
Correia, Manuel
Lyrer, Phillippe
author_sort Sandercock, Peter
collection PubMed
description BACKGROUND: Intravenous recombinant tissue plasminogen activator (rt-PA) is approved for use in selected patients with ischaemic stroke within 3 hours of symptom onset. IST-3 seeks to determine whether a wider range of patients may benefit. DESIGN: International, multi-centre, prospective, randomized, open, blinded endpoint (PROBE) trial of intravenous rt-PA in acute ischaemic stroke. Suitable patients must be assessed and able to start treatment within 6 hours of developing symptoms, and brain imaging must have excluded intracerebral haemorrhage. With 1000 patients, the trial can detect a 7% absolute difference in the primary outcome. With3500 patients, it can detect a 4.0% absolute benefit & with 6000, (mostly treated between 3 & 6 hours), it can detect a 3% benefit. TRIAL PROCEDURES: Patients are entered into the trial by telephoning a fast, secure computerised central randomisation system or via a secure web interface. Repeat brain imaging must be performed at 24–48 hours. The scans are reviewed 'blind' by expert readers. The primary measure of outcome is the proportion of patients alive and independent (Modified Rankin 0–2) at six months (assessed via a postal questionnaire mailed directly to the patient). Secondary outcomes include: events within 7 days (death, recurrent stroke, symptomatic intracranial haemorrhage), outcome at six months (death, functional status, EuroQol). TRIAL REGISTRATION: ISRCTN25765518
format Text
id pubmed-2442584
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-24425842008-07-02 The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke Sandercock, Peter Lindley, Richard Wardlaw, Joanna Dennis, Martin Lewis, Steff Venables, Graham Kobayashi, Adam Czlonkowska, Anna Berge, Eivind Slot, Karsten Bruins Murray, Veronica Peeters, Andre Hankey, Graeme Matz, Karl Brainin, Michael Ricci, Stefano Celani, Maria Grazia Righetti, Enrico Cantisani, Teresa Gubitz, Gord Phillips, Steve Arauz, Antonio Prasad, Kameshwar Correia, Manuel Lyrer, Phillippe Trials Study Protocol BACKGROUND: Intravenous recombinant tissue plasminogen activator (rt-PA) is approved for use in selected patients with ischaemic stroke within 3 hours of symptom onset. IST-3 seeks to determine whether a wider range of patients may benefit. DESIGN: International, multi-centre, prospective, randomized, open, blinded endpoint (PROBE) trial of intravenous rt-PA in acute ischaemic stroke. Suitable patients must be assessed and able to start treatment within 6 hours of developing symptoms, and brain imaging must have excluded intracerebral haemorrhage. With 1000 patients, the trial can detect a 7% absolute difference in the primary outcome. With3500 patients, it can detect a 4.0% absolute benefit & with 6000, (mostly treated between 3 & 6 hours), it can detect a 3% benefit. TRIAL PROCEDURES: Patients are entered into the trial by telephoning a fast, secure computerised central randomisation system or via a secure web interface. Repeat brain imaging must be performed at 24–48 hours. The scans are reviewed 'blind' by expert readers. The primary measure of outcome is the proportion of patients alive and independent (Modified Rankin 0–2) at six months (assessed via a postal questionnaire mailed directly to the patient). Secondary outcomes include: events within 7 days (death, recurrent stroke, symptomatic intracranial haemorrhage), outcome at six months (death, functional status, EuroQol). TRIAL REGISTRATION: ISRCTN25765518 BioMed Central 2008-06-17 /pmc/articles/PMC2442584/ /pubmed/18559104 http://dx.doi.org/10.1186/1745-6215-9-37 Text en Copyright © 2008 Sandercock et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocol
Sandercock, Peter
Lindley, Richard
Wardlaw, Joanna
Dennis, Martin
Lewis, Steff
Venables, Graham
Kobayashi, Adam
Czlonkowska, Anna
Berge, Eivind
Slot, Karsten Bruins
Murray, Veronica
Peeters, Andre
Hankey, Graeme
Matz, Karl
Brainin, Michael
Ricci, Stefano
Celani, Maria Grazia
Righetti, Enrico
Cantisani, Teresa
Gubitz, Gord
Phillips, Steve
Arauz, Antonio
Prasad, Kameshwar
Correia, Manuel
Lyrer, Phillippe
The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke
title The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke
title_full The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke
title_fullStr The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke
title_full_unstemmed The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke
title_short The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke
title_sort third international stroke trial (ist-3) of thrombolysis for acute ischaemic stroke
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442584/
https://www.ncbi.nlm.nih.gov/pubmed/18559104
http://dx.doi.org/10.1186/1745-6215-9-37
work_keys_str_mv AT sandercockpeter thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT lindleyrichard thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT wardlawjoanna thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT dennismartin thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT lewissteff thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT venablesgraham thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT kobayashiadam thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT czlonkowskaanna thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT bergeeivind thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT slotkarstenbruins thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT murrayveronica thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT peetersandre thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT hankeygraeme thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT matzkarl thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT braininmichael thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT riccistefano thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT celanimariagrazia thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT righettienrico thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT cantisaniteresa thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT gubitzgord thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT phillipssteve thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT arauzantonio thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT prasadkameshwar thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT correiamanuel thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT lyrerphillippe thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT thethirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT sandercockpeter thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT lindleyrichard thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT wardlawjoanna thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT dennismartin thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT lewissteff thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT venablesgraham thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT kobayashiadam thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT czlonkowskaanna thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT bergeeivind thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT slotkarstenbruins thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT murrayveronica thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT peetersandre thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT hankeygraeme thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT matzkarl thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT braininmichael thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT riccistefano thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT celanimariagrazia thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT righettienrico thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT cantisaniteresa thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT gubitzgord thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT phillipssteve thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT arauzantonio thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT prasadkameshwar thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT correiamanuel thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT lyrerphillippe thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke
AT thirdinternationalstroketrialist3ofthrombolysisforacuteischaemicstroke